Bio - Carl LeBel, Ph.D.
Carl LeBel, Ph.D.
Dr. LeBel is currently Chief Scientific Officer at Otonomy Inc., where he is responsible for all R&D activities focused on developing pharmacotherapeutics to treat diseases of the ear, including vertigo, otitis media, and hearing loss. Before Otonomy he was President and CEO at Akesis Pharmaceuticals Inc, a virtual metabolic disease firm, and he held numerous R&D management positions during a14-year tenure at Amgen Inc. Prior to that he held pharmacology/toxicology positions at Alkermes Inc. and Arthur D. Little Inc. Dr. LeBel holds a BS in Chemistry from the University of Detroit, a PhD in Biomedical Sciences/Toxicology from Northeastern University, and he was a NIEHS postdoctoral fellow in Community and Environmental Medicine at the University of California, Irvine. Dr. LeBel is also currently Executive Chairman of NuRx Pharmaceuticals Inc., a cancer therapeutics/diagnostics company, and a Director at Ash Stevens Inc, a privately held pharmaceutical contract manufacturer.